Catalyst Biosciences Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$3.35 |
Market Cap |
$111.53 M |
Shares Outstanding |
11.98 M |
Public Float |
9.65 M |
Address |
611 Gateway Boulevard South San Francisco California 94080 United States |
Employees | - |
Website | http://www.catalystbiosciences.com |
Updated | 07/08/2019 |
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration. |